5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases (also called methionine synthases).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Fosphenytoin | The serum concentration of Fosphenytoin can be decreased when it is combined with 5-methyltetrahydrofolic acid. |
| Raltitrexed | The therapeutic efficacy of Raltitrexed can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Sulfasalazine | The serum concentration of 5-methyltetrahydrofolic acid can be decreased when it is combined with Sulfasalazine. |
| Phenytoin | The serum concentration of Phenytoin can be decreased when it is combined with 5-methyltetrahydrofolic acid. |
| Glucarpidase | The serum concentration of the active metabolites of 5-methyltetrahydrofolic acid can be reduced when 5-methyltetrahydrofolic acid is used in combination with Glucarpidase resulting in a loss in efficacy. |
| Phenobarbital | The serum concentration of Phenobarbital can be decreased when it is combined with 5-methyltetrahydrofolic acid. |
| Primidone | The serum concentration of Primidone can be decreased when it is combined with 5-methyltetrahydrofolic acid. |
| Pyrimethamine | The therapeutic efficacy of Pyrimethamine can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Dapsone | The therapeutic efficacy of Dapsone can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Methotrexate | The therapeutic efficacy of Methotrexate can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Pemetrexed | The therapeutic efficacy of Pemetrexed can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Proguanil | The therapeutic efficacy of Proguanil can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Trimetrexate | The therapeutic efficacy of Trimetrexate can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Piritrexim | The therapeutic efficacy of Piritrexim can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Metoprine | The therapeutic efficacy of Metoprine can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Iclaprim | The therapeutic efficacy of Iclaprim can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Pralatrexate | The therapeutic efficacy of Pralatrexate can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Aminopterin | The therapeutic efficacy of Aminopterin can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Lometrexol | The therapeutic efficacy of Lometrexol can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Nolatrexed | The therapeutic efficacy of Nolatrexed can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Brodimoprim | The therapeutic efficacy of Brodimoprim can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Cycloguanil | The therapeutic efficacy of Cycloguanil can be decreased when used in combination with 5-methyltetrahydrofolic acid. |
| Valproic acid | The serum concentration of 5-methyltetrahydrofolic acid can be decreased when it is combined with Valproic acid. |
| Colestipol | The serum concentration of 5-methyltetrahydrofolic acid can be decreased when it is combined with Colestipol. |
| Carbamazepine | The serum concentration of 5-methyltetrahydrofolic acid can be decreased when it is combined with Carbamazepine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Fluorouracil. |
| Flucytosine | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Capecitabine. |
| 5-fluorouridine | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with 5-fluorouridine. |
| Uracil | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Uracil. |
| Tegafur | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Tegafur. |
| Doxifluridine | The risk or severity of adverse effects can be increased when 5-methyltetrahydrofolic acid is combined with Doxifluridine. |
| Pafolacianine | 5-methyltetrahydrofolic acid may decrease effectiveness of Pafolacianine as a diagnostic agent. |